Extracellular vesicles (EVs), are a heterogeneous family of nanoparticles, classified on the basis of size and biogenesis as exosomes, microvesicles and apoptotic bodies. Being released by cells of different origins in both physiological and pathological conditions. EVs are found in multiple body fluids such as plasma, serum, urine, saliva, amniotic fluid, maternal milk and cerebrospinal fluid. Subpopulations of EVs derived from multiple cellular origins possess a variety of cargo, comprising of bioactive molecules like nucleic acids, proteins, lipids and multiple host derived metabolites. In cancer, exosomes mediate complex signaling between cancerous and immune cells and impact the immune escape of tumour cells. Moreover, EVs, being found in easily accessible body fluids, can serve as biomarkers of response to immunotherapy in cancer patients.
Nowadays, only a small percentage of cancer patients benefit from immunotherapies. Thus, there is a growing need to discover the mechanisms of signaling pathways resulting in unsuccessful immunotherapy as well as analyse the endogenous causes leading to therapeutic resistance. Studying the cargo-containing EVs shuttled between tumor cells and immune cells may help to understand cell to cell communication mechanisms which will augment the rational use of immunotherapy to boost the anti-cancer immune response.
This Research Topic will present and discuss original articles, review articles, systematic reviews with or without meta-analyses investigating:
-cancer-derived EV cargo identification and its functions as predictor of response to immunotherapy
-role of EVs as messenger of cell communication in the tumor immune microenvironment
-role of EV cargo as potential biomarkers for immunotherapy response
-role of EVs in immunotherapy resistance
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
Extracellular vesicles (EVs), are a heterogeneous family of nanoparticles, classified on the basis of size and biogenesis as exosomes, microvesicles and apoptotic bodies. Being released by cells of different origins in both physiological and pathological conditions. EVs are found in multiple body fluids such as plasma, serum, urine, saliva, amniotic fluid, maternal milk and cerebrospinal fluid. Subpopulations of EVs derived from multiple cellular origins possess a variety of cargo, comprising of bioactive molecules like nucleic acids, proteins, lipids and multiple host derived metabolites. In cancer, exosomes mediate complex signaling between cancerous and immune cells and impact the immune escape of tumour cells. Moreover, EVs, being found in easily accessible body fluids, can serve as biomarkers of response to immunotherapy in cancer patients.
Nowadays, only a small percentage of cancer patients benefit from immunotherapies. Thus, there is a growing need to discover the mechanisms of signaling pathways resulting in unsuccessful immunotherapy as well as analyse the endogenous causes leading to therapeutic resistance. Studying the cargo-containing EVs shuttled between tumor cells and immune cells may help to understand cell to cell communication mechanisms which will augment the rational use of immunotherapy to boost the anti-cancer immune response.
This Research Topic will present and discuss original articles, review articles, systematic reviews with or without meta-analyses investigating:
-cancer-derived EV cargo identification and its functions as predictor of response to immunotherapy
-role of EVs as messenger of cell communication in the tumor immune microenvironment
-role of EV cargo as potential biomarkers for immunotherapy response
-role of EVs in immunotherapy resistance
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.